Patents by Inventor Heinz Heider

Heinz Heider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Tri-specific Binding Molecules
    Publication number: 20220411533
    Abstract: The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: June 15, 2022
    Publication date: December 29, 2022
    Inventors: Paul ADAM, Stephen R. COMEAU, Philip Nicholas GORMAN, Pankaj Gupta, Priyanka GUPTA, Karl-Heinz HEIDER, Srinath KASTURIRANGAN, Renate KONOPITZKY, Klaus-Peter KUENKELE, Sandeep KUMAR, Taneisha Ann-Tanara MACK, Elinborg Katrin OSTERMANN, Abdulsalam SHAABAN, David WEISMANN, Andreas WERNITZNIG, David S. YOUNG
  • ANTI-CD37 ANTIBODIES
    Publication number: 20210230271
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: November 4, 2020
    Publication date: July 29, 2021
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • CD33 BINDING AGENTS
    Publication number: 20190256593
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Application
    Filed: December 17, 2018
    Publication date: August 22, 2019
    Inventors: Renate KONOPITZKY, Eric BORGES, Paul ADAM, Karl-Heinz HEIDER
  • CD33 binding agents
    Patent number: 10202451
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: February 12, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Renate Konopitzky, Eric Borges, Paul Adam, Karl-Heinz Heider
  • ANTI CD37 ANTIBODIES
    Publication number: 20180186876
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: February 15, 2018
    Publication date: July 5, 2018
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • Anti CD37 antibodies
    Patent number: 9932399
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 3, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
  • PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS
    Publication number: 20180064811
    Abstract: The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 8, 2018
    Inventor: Karl-Heinz HEIDER
  • CD33 BINDING AGENTS
    Publication number: 20170088617
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Inventors: Renate KONOPITZKY, Eric BORGES, Paul ADAM, Karl-Heinz HEIDER
  • CD33 binding agents
    Patent number: 9550833
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: January 24, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Renate Konopitzky, Eric Borges, Paul Adam, Karl-Heinz Heider
  • ANTI CD37 ANTIBODIES
    Publication number: 20160137729
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: April 22, 2015
    Publication date: May 19, 2016
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • COMBINATION OF CD37 ANTIBODIES WITH CHLORAMBUCIL
    Publication number: 20160106837
    Abstract: The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and chlorambucil. The combination of CD37 antibodies and chlorambucilis shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.
    Type: Application
    Filed: June 14, 2013
    Publication date: April 21, 2016
    Inventors: Karl-Heinz HEIDER, Petra BLUM
  • CD33 BINDING AGENTS
    Publication number: 20150284462
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Application
    Filed: June 18, 2015
    Publication date: October 8, 2015
    Inventors: Renate KONOPITZKY, Eric BORGES, Paul ADAM, Karl-Heinz HEIDER
  • SUPERIOR EFFICACY OF CD37 ANTIBODIES IN CLL BLOOD SAMPLES
    Publication number: 20150266967
    Abstract: The present invention describes CD37 antibodies, especially A2 and B2, for the treatment of patients with CLL, especially of patients belonging to a “high risk” or “ultra-high risk” group of patients. Those patients are either patients who are refractory to fludarabine treatment or patients who carry a genetic marker which is indicative for poor prognosis or increased risk of treatment failure, e.g. patients with TP53 dysfunction or deletion of chromosome 17p13, or patients after failure to previous anti-CD20 treatment. The ability of A2 and B2 to deplete CLL cells is high both in patient samples derived from patients with normal risk and with increased risk (“high risk” patients) and clearly superior to that of rituximab and alemtuzumab.
    Type: Application
    Filed: April 13, 2015
    Publication date: September 24, 2015
    Inventors: Stephan STILGENBAUER, Thorsten ZENZ, Karl-Heinz HEIDER
  • COMBINATION OF CD37 ANTIBODIES WITH BENDAMUSTINE
    Publication number: 20150231242
    Abstract: The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and bendamustine. The combination of CD37 antibodies and bendamustine is shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.
    Type: Application
    Filed: May 4, 2015
    Publication date: August 20, 2015
    Inventors: Karl-Heinz HEIDER, Petra BLUM
  • CD33 binding agents
    Patent number: 9079958
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: July 14, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Renate Konopitzky, Eric Borges, Paul Adam, Karl-Heinz Heider
  • Anti CD37 antibodies
    Patent number: 9078879
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 14, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
  • PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS
    Publication number: 20150125447
    Abstract: The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventor: Karl-Heinz HEIDER
  • Combination of CD37 antibodies with ICE
    Patent number: 8992915
    Abstract: The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and ICE. The combination of CD37 antibodies and ICE is shown to have improved anti-tumor efficacy compared to single agent treatment. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: March 31, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Anke Baum, Charlotte Astrid Russell
  • ANTI CD37 ANTIBODIES
    Publication number: 20140010808
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: August 23, 2013
    Publication date: January 9, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • ANTI CD37 ANTIBODIES
    Publication number: 20140004110
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: August 23, 2013
    Publication date: January 2, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN